Aluminium Containing Adjuvants

Vaccine Adjuvants

Vaccine Adjuvants
from David A. G. Skibinski and Derek T. O'Hagan writing in Vaccine Design: Innovative Approaches and Novel Strategies

The development of new effective vaccines, especially those consisting of highly purified antigens, will increasingly require the inclusion of an adjuvant. With over half a century of experience, aluminium containing adjuvants (alum) will continue to be widely used and until very recently remained the only vaccine adjuvant approved for human use in the US. In recent years a number of studies have started to reveal a more detailed understanding of alum's mechanism of action. There is a the need for more potent adjuvants than alum, with particular emphasis on the discovery and development of MF59, an emulsion based vaccine adjuvant which as been licensed for more than ten years in more than 20 countries, for use in an influenza vaccine focused on elderly subjects (Fluad).

Further reading: Vaccine Design: Innovative Approaches and Novel Strategies